CDK2 inhibitor compounds

TW202631619APending Publication Date: 2026-08-01ALEKSIA THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW114144160
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-11-14
Filing Date
2025-11-12
Publication Date
2026-08-01
Patent Text Reader

Abstract

The present disclosure provides CDK2 inhibitor compounds that can have a fused 6-6 bicyclic core, such as a naphthyridine, quinazoline, pyridopyrimidine or related isosteric core structure that is further substituted. Also provided herein are pharmaceutical compositions including the subject CDK2 inhibitor compounds, and methods for using compositions of the disclosure as anticancer therapeutics.
Need to check novelty before this filing date? Find Prior Art